GlassScriptPhysician profile
Joseph D Vandenberg
NPI 1265099170
$7,026.74
in general payments reported to CMS, 2019-2025
27 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $408 · 2021: $898 · 2022: $1,003 · 2023: $1,000 · 2024: $1,293 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,460.30 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,096.68 | 2024-2025 | Xdemvy |
| Abbvie INC. | $902.99 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sight Sciences, INC. | $845.17 | 2021-2025 | Omni Surgical System, Tearcare System |
| Bausch & Lomb Americas INC. | $578.53 | 2022-2025 | Infuse, Xiidra, Miebo |
| Biotissue Holdings INC. | $541.79 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $413.54 | 2019-2021 | |
| Allergan, INC. | $394.42 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $289.45 | 2019-2023 | Cequa |
| Notal Vision, INC. | $278.67 | 2021-2022 | |
| Amgen INC. | $265.44 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $257.00 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $236.11 | 2020-2021 | |
| Alcon Vision LLC | $229.65 | 2022-2025 | Clareon, Total30, Tryptyr |
| Horizon Therapeutics Plc | $121.12 | 2023 | Tepezza |
| Lkc Technologies, INC. | $90.72 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.28 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $54.40 | 2019-2021 | |
| Glaukos Corporation | $52.48 | 2024-2025 | Istent Infinite, Idose |
| Coopervision INC. | $51.15 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $50.60 | 2022-2023 | Acuvue |
| Johnson & Johnson Surgical Vision, INC. | $36.85 | 2023 | Tecnis Iol |
| Oyster Point Pharma, INC. | $35.00 | 2023 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $33.00 | 2022 | |
| Astellas Pharma US INC | $32.75 | 2023 | |
| Coherus Oncology, INC. | $27.88 | 2023 | |
| Eyevance Pharmaceuticals LLC | $21.60 | 2022 | |
| Ocular Therapeutix, INC. | $20.47 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vandenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.